Market Closed -
Nasdaq
04:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
21.07
USD
|
+5.46%
|
|
+15.71%
|
-0.75%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,951
|
2,507
|
2,346
|
1,560
|
1,292
|
1,232
|
-
|
-
|
Enterprise Value (EV)
1 |
1,421
|
1,904
|
2,012
|
933.5
|
553.1
|
755.7
|
1,232
|
1,232
|
P/E ratio
|
74.8
x
|
-36.1
x
|
29.3
x
|
-28
x
|
-10.2
x
|
-5.98
x
|
-7.22
x
|
-12.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
12.4
x
|
20.4
x
|
8.53
x
|
9.48
x
|
7.68
x
|
13.2
x
|
7.9
x
|
4.64
x
|
EV / Revenue
|
9.07
x
|
15.5
x
|
7.31
x
|
5.67
x
|
3.29
x
|
8.1
x
|
7.9
x
|
4.64
x
|
EV / EBITDA
|
78.4
x
|
-26.8
x
|
39.3
x
|
-12.7
x
|
-4.35
x
|
-4.19
x
|
-7.84
x
|
-9.29
x
|
EV / FCF
|
24.9
x
|
-122
x
|
-66.7
x
|
-66.6
x
|
8.3
x
|
-3.55
x
|
-5.78
x
|
-
|
FCF Yield
|
4.01%
|
-0.82%
|
-1.5%
|
-1.5%
|
12.1%
|
-28.2%
|
-17.3%
|
-
|
Price to Book
|
3.3
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
56,721
|
57,455
|
58,482
|
59,924
|
60,875
|
61,647
|
-
|
-
|
Reference price
2 |
34.39
|
43.63
|
40.12
|
26.04
|
21.23
|
19.98
|
19.98
|
19.98
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
156.7
|
122.7
|
275.1
|
164.6
|
168.3
|
93.25
|
155.9
|
265.7
|
EBITDA
1 |
18.12
|
-71
|
51.26
|
-73.67
|
-127.1
|
-180.5
|
-157.1
|
-132.6
|
EBIT
1 |
13.82
|
-76.8
|
43.77
|
-82.47
|
-138.6
|
-214.6
|
-188
|
-103.9
|
Operating Margin
|
8.82%
|
-62.59%
|
15.91%
|
-50.11%
|
-82.36%
|
-230.17%
|
-120.57%
|
-39.09%
|
Earnings before Tax (EBT)
1 |
27.19
|
-69.33
|
82.63
|
-54.51
|
-120.4
|
-194.2
|
-169
|
-92.4
|
Net income
1 |
26.88
|
-69.33
|
82.63
|
-55.18
|
-126.1
|
-203.9
|
-171.5
|
-99.94
|
Net margin
|
17.15%
|
-56.51%
|
30.04%
|
-33.53%
|
-74.9%
|
-218.68%
|
-109.99%
|
-37.61%
|
EPS
2 |
0.4600
|
-1.210
|
1.370
|
-0.9300
|
-2.080
|
-3.339
|
-2.769
|
-1.598
|
Free Cash Flow
1 |
57.02
|
-15.54
|
-30.15
|
-14.01
|
66.66
|
-213
|
-213
|
-
|
FCF margin
|
36.39%
|
-12.67%
|
-10.96%
|
-8.51%
|
39.6%
|
-228.41%
|
-136.64%
|
-
|
FCF Conversion (EBITDA)
|
314.65%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
212.17%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
19.68
|
154
|
85.5
|
30.18
|
27.3
|
21.61
|
18.96
|
45.52
|
59.16
|
44.69
|
24.99
|
24.52
|
24.62
|
25.6
|
34.11
|
EBITDA
1 |
-39.31
|
93.76
|
28.64
|
-25.78
|
-36.11
|
-40.43
|
-57.12
|
-23.11
|
-15.13
|
-30.4
|
-28.34
|
-28.33
|
-28.71
|
-29.26
|
-32.81
|
EBIT
1 |
-41.3
|
91.65
|
26.47
|
-28
|
-38.35
|
-42.59
|
-59.36
|
-26
|
-18.27
|
-33.63
|
-49.57
|
-52.24
|
-53.58
|
-52.45
|
-46.52
|
Operating Margin
|
-209.83%
|
59.51%
|
30.96%
|
-92.79%
|
-140.47%
|
-197.1%
|
-313.07%
|
-57.11%
|
-30.88%
|
-75.25%
|
-198.34%
|
-213.02%
|
-217.6%
|
-204.9%
|
-136.4%
|
Earnings before Tax (EBT)
1 |
-40.19
|
73.06
|
23.59
|
-33.98
|
-31.67
|
-12.46
|
-60.76
|
-21.95
|
-24.27
|
-13.45
|
-44.73
|
-47.14
|
-51.43
|
-50.79
|
-44.78
|
Net income
1 |
-40.19
|
73.06
|
23.59
|
-33.98
|
-32.76
|
-12.04
|
-60.76
|
-21.95
|
-24.27
|
-19.1
|
-47.58
|
-49.39
|
-52.87
|
-51.97
|
-44.78
|
Net margin
|
-204.19%
|
47.44%
|
27.6%
|
-112.59%
|
-120%
|
-55.72%
|
-320.45%
|
-48.23%
|
-41.02%
|
-42.74%
|
-190.38%
|
-201.39%
|
-214.71%
|
-203%
|
-131.27%
|
EPS
2 |
-0.6900
|
1.210
|
0.3900
|
-0.5700
|
-0.5500
|
-0.2000
|
-1.020
|
-0.3700
|
-0.4000
|
-0.3100
|
-0.7782
|
-0.8049
|
-0.8625
|
-0.8476
|
-0.7900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
2/23/22
|
5/5/22
|
8/3/22
|
11/7/22
|
2/23/23
|
5/8/23
|
8/3/23
|
11/7/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
530
|
603
|
334
|
627
|
739
|
476
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
57
|
-15.5
|
-30.2
|
-14
|
66.7
|
-213
|
-213
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-7.55%
|
-18.1%
|
-30.6%
|
-30.9%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-6.55%
|
-14%
|
-27%
|
-27.3%
|
-
|
Assets
1 |
-
|
-
|
-
|
842.2
|
899.5
|
755.2
|
627
|
-
|
Book Value Per Share
|
10.40
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
1.100
|
-
|
-
|
-
|
1.410
|
-5.060
|
-1.160
|
-
|
Capex
1 |
7.35
|
10.5
|
13.3
|
38.5
|
18.4
|
39
|
43
|
-
|
Capex / Sales
|
4.69%
|
8.59%
|
4.83%
|
23.39%
|
10.96%
|
41.82%
|
27.58%
|
-
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
21.07
USD Average target price
36.18
USD Spread / Average Target +71.72% Consensus |
1st Jan change
|
Capi.
|
---|
| -0.75% | 1.23B | | -2.63% | 103B | | +1.62% | 95.28B | | +1.46% | 22.15B | | -16.67% | 21.02B | | -8.58% | 18.15B | | -38.74% | 16.73B | | -13.21% | 16.05B | | +5.41% | 13.68B | | +33.57% | 12.17B |
Bio Therapeutic Drugs
|